Cambridge, United Kingdom · Est. 1913 · 89,000 employees
Global biopharmaceutical company focused on prescription medicines.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 15 drugs with upcoming expirations
Pipeline
By Phase
118 drugs in development
By Therapeutic Area
top 6
R&D Momentum
100/100
Pipeline Velocity
100/100
Trial Completion Rate
88/100
Pipeline Concentration
26/100
Pipeline Freshness
69/100
Strategic Signals
Activity
Last 14 days
Phase I/II Dose Escalation & Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-guided T Cell-engaging Antibody That Targets STEAP2, in Adult Participants With Prostate Cancer
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
Boosting Regional Integration for COPD Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle: A Multicentre , Prospective, Cluster Randomization, Inteventional Clinical Study
A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)
A Randomized, Double-blind, Multicenter, Parallel-group, Phase IIIb 52 Week Study Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered as Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA)
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE)
A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)
A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Details
Company Overview
$240.0B
Mkt Cap
$45.8B
Revenue
$6.9B
Cash
Therapeutic Focus
Pipeline
Regulatory
Imfinzi — IMFINZI
Application BLA761069
Brilinta — BRILINTA
Application NDA022433
Imfinzi — IMFINZI
Application BLA761069
Koselugo — KOSELUGO
Application NDA219943 (NDA)
Lynparza — LYNPARZA
Application NDA208558
Imfinzi — IMFINZI
Application BLA761069
Imfinzi — IMFINZI
Application BLA761069
Calquence — CALQUENCE
Application NDA210259
Calquence — CALQUENCE
Application NDA216387
Imfinzi — IMFINZI
Application BLA761069
Saphnelo — SAPHNELO
Application BLA761123
Farxiga — FARXIGA
Application NDA202293
Imfinzi — IMFINZI
Application BLA761069
Baxfendy — BAXFENDY
Application NDA219878 (NDA)
Fasenra — FASENRA
Application BLA761070
Brilinta — BRILINTA
Application NDA022433
Saphnelo — SAPHNELO
Application BLA761451 (BLA)
Saphnelo — SAPHNELO
Application BLA761451
Calquence — CALQUENCE
Application NDA210259
Calquence — CALQUENCE
Application NDA216387
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)